#SARSCoV2 mRNA vaccine development enabled by prototype pathogen preparedness
![]() 3562 Saturday, 13 June, 2020, 18:35 A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation. |
SpaceX Starship rocket explodes during test flight (video)
199719.06.2025, 12:34Elon Musk announces XChat feature
393402.06.2025, 13:04The world's lowest car has been created in Taiwan (video)
582426.05.2025, 11:40Tesla Robot Optimus Learns to Dance (video)
609313.05.2025, 10:21A possible sign of life on K2-18b? Here’s what it means- and why it's just the beginning (video)
945921.04.2025, 01:16Musk: "Armenia is the 130th country where Starlink is already available"
937628.03.2025, 09:51Elon Musk plans to create an "army" of Optimus humanoid robots
982825.03.2025, 12:09China’s commercial Mach-4 drone tipped to make first flight next year
1483523.01.2025, 19:38